PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announced today that a recent clinical study supporting the predictive value of the ChemoFx® chemoresponse assay in recurrent ovarian cancer was presented at the 2013 European Cancer Congress (ECCO-ESMO-ESTRO), held September 27 – October 1, 2013 in Amsterdam, Netherlands. The study, titled, Evaluation of a Chemoresponse Assay as Both a Prognostic and Predictive Marker in the Treatment of Persistent or Recurrent Ovarian Cancer, was presented as part of the “Diagnostics/Biomarkers” session of the biennial conference.
Help employers find you! Check out all the jobs and post your resume.
